Information Provided By:
Fly News Breaks for December 5, 2019
Dec 5, 2019 | 08:04 EDT
JPMorgan analyst Jessica Fye says that while the stock is up ~26% off of its recent October lows, she continues to see an attractive entry point in Jazz Pharmaceuticals shares. The analyst notes that the stock trading at 9.5 times her 2020 earnings estimate. After meeting with management, Fye sees a "fast ramp" for JZP-258 and the potential for JZP-458 to achieve what Erwinaze has been unable to due to supply constraints. She keeps an Overweight rating on the shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ